Summary: An opioid analgesic made from MORPHINE and used mainly as an analgesic. It has a shorter duration of action than morphine.
Publications197 found, 100 shown here
- Opioid equianalgesic conversion: the right doseJ M Brant
Saint Vincent Healthcare, Billings, MT, USA
Clin J Oncol Nurs 5:163-5. 2001..Nurses also play a role in recommending the change and ensuring that patients receive the correct dose...
- Safety and efficacy of hydromorphone as an analgesic alternative to morphine in acute pain: a randomized clinical trialAndrew K Chang
Department of Emergency Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY 10467, USA
Ann Emerg Med 48:164-72. 2006We compare a standard weight-based dose of intravenous hydromorphone (Dilaudid) to a standard weight-based dose of intravenous morphine in adults presenting to the ED with acute severe pain.
- Simultaneous determination of codeine, morphine, hydrocodone, hydromorphone, oxycodone, and 6-acetylmorphine in urine, serum, plasma, whole blood, and meconium by LC-MS-MSRebecka Coles
ARUP Institute for Clinical and Experimental Pathology, ARUP Laboratories Inc, Salt Lake City, Utah 84108, USA
J Anal Toxicol 31:1-14. 2007..The six opiates included are codeine, morphine, hydrocodone, hydromorphone, oxycodone, and 6-acetylmorphine (6-AM)...
- Clinical experience with transdermal and orally administered opioids in palliative care patients--a retrospective studyKatri Elina Clemens
Department of Science and Research, Centre for Palliative Medicine, University of Bonn, Germany
Jpn J Clin Oncol 37:302-9. 2007..We thus retrospectively examined the pain management and need for opioid switching in cancer patients admitted to our palliative care unit...
- The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusersSharon L Walsh
Department of Behavioral Sciences, Center on Drug and Alcohol Research, University of Kentucky, 515 Oldham Court, Lexington, KY 40502, USA
Drug Alcohol Depend 98:191-202. 2008..the relative abuse potential and potency of oral oxycodone (10, 20 and 40 mg), hydrocodone (15, 30 and 45 mg), hydromorphone (10, 17.5 and 25mg) and placebo...
- Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humansS L Walsh
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
Psychopharmacology (Berl) 157:151-62. 2001....
- Once-daily OROS hydromorphone ER compared with placebo in opioid-tolerant patients with chronic low back painM Hale
Gold Coast Research, LLC, Weston, FL 33331, USA
Curr Med Res Opin 26:1505-18. 2010..placebo-controlled study using a randomized withdrawal design evaluated the efficacy and safety of once-daily OROS hydromorphone ER in the treatment of opioid-tolerant patients with chronic moderate-to-severe low back pain (LBP).
- Double-blind injectable hydromorphone versus diacetylmorphine for the treatment of opioid dependence: a pilot studyEugenia Oviedo-Joekes
School of Population and Public Health, University of British Columbia, BC, Canada
J Subst Abuse Treat 38:408-11. 2010..randomized and parallel arm trial, this pilot study is aimed at testing if treatment response with injectable hydromorphone differs compared to diacetylmorphine in the treatment of long-term opioid addiction...
- Efficacy and safety profile of a single dose of hydromorphone compared with morphine in older adults with acute, severe pain: a prospective, randomized, double-blind clinical trialAndrew K Chang
Department of Emergency Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York 10467, USA
Am J Geriatr Pharmacother 7:1-10. 2009..Over the past 10 years, there has been an 11% increase in the number of emergency department (ED) visits by older adults, and pain is their most common chief complaint...
- Pharmacokinetics and physiological effects of intravenous hydromorphone in conscious dogsA G P Guedes
Department of Veterinary Small Animal Clinical Sciences, College of Veterinary Medicine, Texas A and M University, College Station, TX 77843 4474, USA
J Vet Pharmacol Ther 31:334-43. 2008This study evaluated the pharmacokinetics, the sedative and anti-nociceptive effects of intravenous hydromorphone in dogs. Five adult dogs were administered hydromorphone (0.1 mg/kg and 0.2 mg/kg) and morphine (0...
- Results of a double-blind, placebo-controlled, fixed-dose assessment of once-daily OROS® hydromorphone ER in patients with moderate to severe pain associated with chronic osteoarthritisRichard Rauck
Anesthesiology Pain Management, The Carolinas Pain Institute, Winston Salem, NC 27103, USA
Pain Pract 13:18-29. 2013..The objective of this study was to evaluate the efficacy and safety of OROS hydromorphone extended-release (ER) compared with placebo in patients with moderate to severe pain associated with OA.
- The pharmacokinetics of a long-acting OROS hydromorphone formulationJ Turgeon
Centre Hospitalier de l Universite de Montreal, Hotel Dieu, Masson Pavilion, 3850 Saint Urbain Street, Room 8 109, Montreal, Quebec H2W 1T7, Canada
Expert Opin Drug Deliv 7:137-44. 2010..New formulations of opiods can provide round-the-clock pain relief to improve pain management and quality of life for patients with chronic pain...
- Two milligrams i.v. hydromorphone is efficacious for treating pain but is associated with oxygen desaturationAndrew K Chang
Department of Emergency Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, USA
J Opioid Manag 5:75-80. 2009To evaluate the safety and efficacy of a single dose of 2 mg i.v. hydromorphone administered to emergency department patients in acute severe pain.
- Steady-state pharmacokinetics of extended-release hydromorphone (OROS hydromorphone): a randomized study in healthy volunteersKenneth Todd Moore
Johnson and Johnson Pharmaceutical Research and Development, Titusville, New Jersey, USA
J Opioid Manag 6:351-8. 2010The steady-state pharmacokinetics of an extended-release formulation of hydromorphone, OROS hydromorphone, was investigated in a randomized, open-label, crossover study in healthy volunteers...
- Comparison of plasma histamine levels after intravenous administration of hydromorphone and morphine in dogsA G P Guedes
Department of Veterinary Small Animal Clinical Sciences, College of Veterinary Medicine, Texas A and M University, College Station, TX 77843 4474, USA
J Vet Pharmacol Ther 30:516-22. 2007..histamine concentrations, behavioral and cardiovascular parameters following intravenous administration of hydromorphone and morphine in conscious dogs...
- Conversion from standard opioid therapy to once-daily oral extended-release hydromorphone in patients with chronic cancer painM Wallace
San Diego Medical Center, University of California, La Jolla, California, USA
J Int Med Res 36:343-52. 2008This open-label, multicenter study assessed the efficacy and tolerability of conversion to once-daily OROS hydromorphone from previous opioid agonist therapy in patients with chronic cancer pain...
- Opioid switch in palliative care, opioid choice by clinical need and opioid availabilityH C Müller-Busch
PalliativZentrum Berlin Brandenburg, D 10557 Berlin, Germany
Eur J Pain 9:571-9. 2005..Recommendation of first line therapy and availability of opioid formulations define the frequency of opioid use. This impedes evaluation of specific differences between the opioids...
- Open-label study on the long-term efficacy, safety, and impact on quality of life of OROS hydromorphone ER in patients with chronic low back painMark Wallace
Center for Pain Medicine, Department of Anesthesiology, University of California, San Diego School of Medicine, La Jolla, California 92037 7650, USA
Pain Med 11:1477-88. 2010To investigate the efficacy, safety, and impact on quality of life of long-term administration of OROS hydromorphone ER (8-128mg) in patients with chronic low back pain.
- OROS® hydromorphone in chronic pain management: when drug delivery technology matches clinical needsF Coluzzi
Department of Medical and Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, I C O T, Latina, Italy
Minerva Anestesiol 76:1072-84. 2010..In addition, once-daily formulations ensure better patient compliance to prescribed therapies. Hydromorphone was the first opioid to be formulated as a once-daily preparation using OROS® technology...
- A randomized study to demonstrate noninferiority of once-daily OROS(®) hydromorphone with twice-daily sustained-release oxycodone for moderate to severe chronic noncancer painHeinrich Binsfeld
Schmerz Zentrum am St Franziskus Hospital Ahlen, Ahlen, Germany
Pain Pract 10:404-15. 2010..comparative, parallel group study designed to demonstrate the noninferiority of once-daily OROS(®) hydromorphone compared with twice-daily sustained-release (SR) oxycodone in subjects with chronic noncancer pain severe ..
- The effects of fentanyl-like opioids and hydromorphone on human 5-HT3A receptorsMaria Wittmann
Klinik und Poliklinik für Anästhesiologie und operative Intensivmedizin, Universitatskliniken Bonn, Bonn, Germany
Anesth Analg 107:107-12. 2008..Therefore, another morphine (phenanthrene-type) derivative, hydromorphone, and fentanyl including its (4-anilinopiperidine-type) derivatives were tested.
- Comparative clinical effects of hydromorphone and morphine: a meta-analysisL Felden
Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Theodor Stern Kai 7, D 60590 Frankfurt am Main, Germany
Br J Anaesth 107:319-28. 2011We have conducted a meta-analysis of the clinical effects of morphine and hydromorphone to compare their benefit in analgesia...
- Hydromorphone in the management of cancer-related pain: an update on routes of administration and dosage formsMaansi G Kumar
College of Pharmacy and Allied Health Professions, St John s University, Jamaica, New York, USA
J Pharm Pharm Sci 10:504-18. 2007..However, recently focus has shifted to the use of hydromorphone, a semi-synthetic derivative of morphine, which is more potent, more soluble and has a comparable side-effect ..
- A systematic review of hydromorphone in acute and chronic painColumba Quigley
Cancer Center, Hammersmith Hospital, London, United Kingdom
J Pain Symptom Manage 25:169-78. 2003..For these patients, alternatives such as hydromorphone are recommended. This review explores the evidence for the efficacy of hydromorphone in the management of pain...
- Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphineStefan Wirz
Clinic for Anesthesiology and Intensive Care Medicine, Pain Clinic, University of Bonn, Sigmund Freud Strasse 25, D 53105 Bonn, Germany
Eur J Pain 13:737-43. 2009The purpose of this trial was to evaluate the effect of long-term treatment with oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine on nausea, emesis and constipation.
- Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolitesM T Smith
School of Pharmacy, University of Queensland, St Lucia, Australia
Clin Exp Pharmacol Physiol 27:524-8. 2000..myoclonus, seizures) in patients administered large doses of systemic morphine or its structural analogue, hydromorphone (HMOR), has also increased. 4...
- Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, metJoseph Pergolizzi
Johns Hopkins University, Baltimore, Maryland, USA
Pain Pract 8:287-313. 2008..Slow dose titration helps to reduce the incidence of typical initial adverse events such as nausea and vomiting. Sustained release preparations, including transdermal formulations, increase patient compliance...
- Hydromorphone for acute and chronic painC Quigley
Medical Oncology, Hammersmith Hospitals Trust, Du Cane Road, London, UK, W12 0NN
Cochrane Database Syst Rev . 2002..For these patients alternatives such as hydromorphone are recommended...
- Pharmacodynamics of orally administered sustained- release hydromorphone in humansM S Angst
Department of Anesthesia, Stanford University School of Medicine, California 94305 5117, USA
Anesthesiology 94:63-73. 2001The disposition kinetics of hydromorphone generally necessitates oral administration every 4 h of the conventional immediate-release tablet to provide sustained pain relief...
- Retrospective study of the use of hydromorphone in palliative care patients with normal and abnormal urea and creatinineM A Lee
Department of Palliative Medicine, Roxburghe House, Milltimber, Aberdeen AB13 0HR, UK
Palliat Med 15:26-34. 2001An uncontrolled retrospective study was conducted looking at the use of oral controlled-release hydromorphone in palliative care patients...
- Morphine and alternative opioids in cancer pain: the EAPC recommendationsG W Hanks
Palliative Medicine, University of Bristol, Bristol Haematology and Oncology Centre, UK
Br J Cancer 84:587-93. 2001..Practical strategies for dealing with difficult situations are described presenting a consensus view where supporting evidence is lacking. The strength of the evidence on which each recommendation is based is indicated...
- Pitfalls of opioid rotation: substituting another opioid for methadone in patients with cancer painNatalie Moryl
Pain and Palliative Care Service, Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Pain 96:325-8. 2002..A uniformly accepted conversion ratio for substituting methadone with another opioid is currently not available. More data on the rotation from methadone to other opioids are needed...
- Evaluation of the abuse potential of extended release hydromorphone versus immediate release hydromorphoneMegan J Shram
Clinical Pharmacology Group, Kendle Early Stage, Toronto, Ontario, Canada
J Clin Psychopharmacol 30:25-33. 2010Immediate release (IR) hydromorphone has experienced significant misuse and abuse...
- Less nausea, emesis, and constipation comparing hydromorphone and morphine? A prospective open-labeled investigation on cancer painS Wirz
Clinic for Anesthesiology and Intensive Care Medicine, Pain Clinic Department, University of Bonn, Sigmund Freud Strasse 25, Bonn, Germany
Support Care Cancer 16:999-1009. 2008The purpose of this trial was to evaluate the effect of long-term treatment with either oral sustained-release hydromorphone (HM) or morphine (M) on nausea, emesis, and constipation.
- Effect of intravenous injection speed on responses to cocaine and hydromorphone in humansM E Abreu
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21224-6823, USA
Psychopharmacology (Berl) 154:76-84. 2001..speed on the pharmacodynamic responses related to abuse liability and toxicity of intravenous cocaine and hydromorphone. METHODS: Twelve experienced opiate and cocaine users completed this 3-week inpatient study...
- Long-term safety, tolerability, and efficacy of OROS hydromorphone in patients with chronic painMark Wallace
San Diego Medical Center, University of California, La Jolla, California, USA
J Opioid Manag 5:97-105. 2009To assess the safety and efficacy of long-term repeated dosing of OROS hydromorphone in chronic pain patients.
- The role of spinal opioid receptors in antinociceptive effects produced by intrathecal administration of hydromorphone and buprenorphine in the ratGopi A Tejwani
Department of Pharmacology, College of Medicine and Public Health, Ohio State University, 5197 Graves Hall, 333 W 10th Avenue, Columbus, OH 43210 1239, USA
Anesth Analg 94:1542-6, table of contents. 2002..lack of efficacy or because of the side effects produced by morphine in some patients, other drugs, such as hydromorphone and buprenorphine, should be investigated for their analgesic properties...
- Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphoneAlexandra Ward
Caro Research Institute, Concord, MA 01742, USA
Curr Med Res Opin 23:2333-45. 2007The Osmotic controlled-Release Oral delivery System (OROS) hydromorphone ensures continuous release of hydromorphone over 24 hours. It is anticipated that this will facilitate optimal pain relief, improve quality of sleep and compliance...
- Hydromorphone: pharmacology and clinical applications in cancer patientsN Sarhill
Harry R. Horvitz Center for Palliative Medicine, Taussig Cancer Center of Cleveland Clinic Foundation, Cleveland, Ohio, USA
Support Care Cancer 9:84-96. 2001b>Hydromorphone is a more potent opioid analgesic than morphine and is used for moderate to severe pain. It can be administered by injection, by infusion, by mouth, and rectally. Oral bioavailability is low...
- Relief of incident dyspnea in palliative cancer patients: a pilot, randomized, controlled trial comparing nebulized hydromorphone, systemic hydromorphone, and nebulized salineMargaret A Charles
School of Psychology, Sydney University, Sydney, New South Wales, Australia
J Pain Symptom Manage 36:29-38. 2008..This pilot, double-blind, controlled, crossover study compared the effects of nebulized hydromorphone, systemic hydromorphone and nebulized saline for the relief of episodic breathlessness in advanced cancer ..
- Managing cancer pain and symptoms of outpatients by rotation to sustained-release hydromorphone: a prospective clinical trialStefan Wirz
Clinic for Anesthesiology and Intensive Care Medicine, Pain Clinic Department, University of Bonn, Sigmund Freud Str 25, D 53105 Bonn, Germany
Clin J Pain 22:770-5. 2006In this prospective clinical trial we examined the technique of opioid rotation to oral sustained-release hydromorphone for controlling pain and symptoms in outpatients with cancer pain.
- HydromorphoneAlison Murray
Department of Family Medicine, Division of Palliative Medicine, University of Calgary, Calgary, Alberta, Canada
J Pain Symptom Manage 29:S57-66. 2005b>Hydromorphone is a semi-synthetic opioid that has been used widely for acute pain, chronic cancer pain and to a lesser extent, in chronic nonmalignant pain...
- Comparative efficacy of oral extended-release hydromorphone and immediate-release hydromorphone in patients with persistent moderate to severe pain: two randomized controlled trialsAlan B Grosset
North Idaho Cancer Center, Coeur d Alene, Idaho 83814, USA
J Pain Symptom Manage 29:584-94. 2005..double-blind, crossover studies with identical designs evaluated the efficacy of oral extended-release hydromorphone (HHER) administered q24h compared with immediate-release hydromorphone (HHIR) dosed four times daily in ..
- Effect of hydromorphone on ventilation in palliative care patients with dyspneaKatri Elina Clemens
Department of Anaesthesiology, Intensive Care Medicine, Palliative Medicine and Pain Therapy, Malteser Hospital Bonn Rhein Sieg, Von Hompesch Strasse 1, Bonn, Germany
Support Care Cancer 16:93-9. 2008This study assessed the effect of hydromorphone treatment on ventilation and the intensity of dyspnea in palliative care patients...
- Clinical pharmacology and pharmacokinetics of once-daily hydromorphone hydrochloride extended-release capsulesVijay Vashi
Purdue Pharma, LP, One Stamford Forum, Stamford, CT 06901 3431, USA
J Clin Pharmacol 45:547-54. 2005b>Hydromorphone hydrochloride extended release (HHER) is a multiparticulate melt-extrusion pellet capsule formulation administered q24h...
- Hydromorphone-3-glucuronide: a more potent neuro-excitant than its structural analogue, morphine-3-glucuronideA W Wright
School of Pharmacy, The University of Queensland, Brisbane, Australia
Life Sci 69:409-20. 2001In humans, hydromorphone (HMOR) is metabolised principally by conjugation with glucuronic acid to form hydromorphone-3-glucuronide (H3G), a close structural analogue of morphine-3-glucuronide (M3G), the major metabolite of morphine...
- Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence of alcoholG Sathyan
ALZA Corporation, 1900 Charleston Road, Mountain View, California 94039, USA
Curr Med Res Opin 24:297-305. 2008The purpose of this study was to investigate the pharmacokinetic properties of a novel, once-daily, controlled-release formulation of hydromorphone (OROS hydromorphone) in the presence of alcohol.
- The side effects of morphine and hydromorphone patient-controlled analgesiaDaewha Hong
Department of Anesthesiology, Columbia University Medical Center, 630 West 168th St New York City, NY 10032, USA
Anesth Analg 107:1384-9. 2008Despite "clinical lore" among health care providers that treatment with hydromorphone results in improved pain control and fewer adverse side effects, morphine continues to be the first-line medication for postoperative patient-..
- Antinociceptive effects of hydromorphone, bupivacaine and biphalin released from PLGA polymer after intrathecal implantation in ratsD Sendil
Biotechnology Research Unit, Department of Biological Sciences, Middle East Technical University, 06531, Ankara, Turkey
Biomaterials 24:1969-76. 2003..copolymer poly(L-lactide-co-glycolide) (PLGA) was used to prepare a rod-shaped drug delivery system containing hydromorphone (HM), bupivacaine (BP), both HM and BP, or biphalin (BI)...
- Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence and absence of foodGayatri Sathyan
ALZA Corporation, Mountain View, CA, USA
BMC Clin Pharmacol 7:2. 2007..study was to compare the pharmacokinetic profile of a novel, once-daily, controlled-release formulation of hydromorphone (OROS hydromorphone) under fasting conditions with that immediately after a high-fat breakfast in healthy ..
- Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe painSharon M Weinstein
MD Anderson Cancer Center, University o f Texas, Houston, Texas, USA
Clin Ther 28:86-98. 2006b>Hydromorphone hydrochloride is a mu-opioid agonist with dose-dependent analgesic properties. Extended-release hydromorphone hydrochloride (ER hydromorphone HCl) capsules have been developed for administration every 24 hours.
- Hydromorphone metabolites: isolation and identification from pooled urine samples of a cancer patientM Zheng
Faculty of Pharmaceutical Sciences, University of British Columbia, 2146 East Mall, Vancouver, BC V6T 1Z3, Canada
Xenobiotica 32:427-39. 20021. Hydromorphone-3-glucuronide, dihydromorphine, dihydroisomorphine, dihydromorphine-3-glucuronide and dihydroisomorphine-3-glucuronide were isolated from a cancer patient's urine and identified as metabolites of hydromorphone by ..
- A comparison of single-dose caudal clonidine, morphine, or hydromorphone combined with ropivacaine in pediatric patients undergoing ureteral reimplantationThomas R Vetter
Department of Anesthesia, Indiana University School of Medicine, Indianapolis, Indiana, USA
Anesth Analg 104:1356-63, table of contents. 2007..We prospectively compared the analgesic, side effect, and rehabilitation profiles of caudal clonidine, hydromorphone, or morphine in a group of 60 pediatric patients undergoing ureteral reimplantation.
- Successful reduction of neuropathic pain associated with spinal cord injury via of a combination of intrathecal hydromorphone and ziconotide: a case reportM Saulino
Moss Rehab, Department of Rehabilitation Medicine, Thomas Jefferson University, Elkins Park, PA, USA
Spinal Cord 45:749-52. 2007..Case report...
- GC-MS quantitation of codeine, morphine, 6-acetylmorphine, hydrocodone, hydromorphone, oxycodone, and oxymorphone in bloodRobert Meatherall
Department of Biochemistry, St Boniface General Hospital, Winnipeg, Manitoba, Canada
J Anal Toxicol 29:301-8. 2005..is described for the simultaneous analysis of seven opiates, codeine, morphine, 6-acetylmorphine, hydrocodone, hydromorphone, oxycodone, and oxymorphone, in blood samples by gas chromatography-mass spectrometry (GC-MS)...
- GC-MS confirmation of codeine, morphine, 6-acetylmorphine, hydrocodone, hydromorphone, oxycodone, and oxymorphone in urineR Meatherall
Department of Biochemistry, St Boniface General Hospital, Winnipeg, Manitoba, Canada
J Anal Toxicol 23:177-86. 1999A procedure for the simultaneous confirmation of codeine, morphine, 6-acetylmorphine, hydrocodone, hydromorphone, oxycodone, and oxymorphone in urine specimens by gas chromatography-mass spectrometry (GC-MS) is described...
- The role of hydromorphone in cancer pain treatment: a systematic reviewAlessandra Pigni
Fondazione IRCCS Istituto Nazionale Tumori Milano, Italy
Palliat Med 25:471-7. 2011The aim of this systematic review is to evaluate the scientific evidence for the efficacy and side effects of hydromorphone in the management of moderate to severe cancer pain...
- Pharmacokinetics of hydromorphone hydrochloride in healthy dogsButch KuKanich
PharmCATS and the Department of Anatomy and Physiology, Kansas State University, Manhattan, KS, USA
Vet Anaesth Analg 35:256-64. 2008To assess the pharmacokinetics of hydromorphone administered intravenously (IV) or subcutaneously (SC) to dogs.
- Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysisMartin Hale
Gold Coast Research LLC, Weston, FL, USA
Clin Ther 29:874-88. 2007This study compared the efficacy and tolerability of a once-daily controlled-release formulation of hydromorphone (OROS) hydromorphone, Janssen-Cilag, Beerse, Belgium) and twice-daily extended-release (ER) oxycodone in patients with ..
- A randomized study of the effect of oral lamotrigine and hydromorphone on pain and hyperalgesia following heat/capsaicin sensitizationKarin L Petersen
Pain Clinical Research Center and Department of Neurology, University of California, San Francisco, CA 94115, USA
J Pain 4:400-6. 2003..sensitization induced with the heat/capsaicin sensitization model was compared with the effect of oral hydromorphone (8 mg) in healthy volunteers. In a separate session, intravenous remifentanil (0.10 microg.kg(-1)...
- Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant painMark Palangio
Abbott Laboratories, Morris Corporate Center, Parsippany, New Jersey 07054, USA
J Pain Symptom Manage 23:355-68. 2002..conversion from prior opioid therapy to a novel, once-daily, OROS osmotic technology, extended-release (ER) hydromorphone formulation in an outpatient population with chronic malignant or nonmalignant pain...
- Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteersDavid R Drover
Department of Anesthesia, Stanford University School of Medicine, California 94305 5940, USA
Anesthesiology 97:827-36. 2002To compare the pharmacokinetics of intravenous, oral immediate-release (IR), and oral extended-release (OROS ) formulations of hydromorphone.
- Antinociceptive effects of hydromorphone, butorphanol, or the combination in catsB Duncan X Lascelles
College of Veterinary Medicine, University of Florida, Gainesville, USA
J Vet Intern Med 18:190-5. 2004The goal of this study was to assess the antinociceptive activity of a single dose of hydromorphone or butorphanol and to examine the effect of their coadministration on thermal thresholds in cats...
- A multiple-dose phase I study of intranasal hydromorphone hydrochloride in healthy volunteersAnita C Rudy
Intranasal Technology, Inc, Coldstream Research Campus, 1513 Bull Lea Blvd, Lexington, KY 40511 1200, USA
Anesth Analg 99:1379-86; table of contents. 2004We evaluated the pharmacokinetics, tolerability, and safety of 1 and 2 mg of intranasal hydromorphone hydrochloride in an open-label, single- and multiple-dose study...
- Secondary adrenal failure and secondary amenorrhoea following hydromorphone treatmentKarsten Müssig
Clin Endocrinol (Oxf) 66:604-5. 2007
- Efficacy and safety evaluation of once-daily OROS hydromorphone in patients with chronic low back pain: a pilot open-label study (DO-127)Mark Wallace
University of California, San Diego Medical Center, La Jolla, CA, USA
Curr Med Res Opin 23:981-9. 2007To evaluate the safety, tolerability, and efficacy of once-daily osmotic controlled-release oral delivery system (OROS) hydromorphone in patients with chronic low back pain of moderate-to-severe intensity.
- Pharmacokinetic investigation of dose proportionality with a 24-hour controlled-release formulation of hydromorphoneGayatri Sathyan
ALZA Corporation, Mountain View, CA, USA
BMC Clin Pharmacol 7:3. 2007The purpose of this study was investigate the dose proportionality of a novel, once-daily, controlled-release formulation of hydromorphone that utilizes the OROS Push-Pull osmotic pump technology.
- Once-daily OROS hydromorphone for the management of chronic nonmalignant pain: a dose-conversion and titration studyM Wallace
San Diego Medical Center, University of California, La Jolla, CA, USA
Int J Clin Pract 61:1671-6. 2007..The use of opioid analgesics for patients with chronic nonmalignant pain is becoming more widely accepted, and long-acting formulations are an important treatment option...
- [Pain reduced and quality of life improved by sustained-release hydromorphone. Results of an observational study]H B Sittig
Leiter Schmerztherapie Zentrum Unterweser, St Josef Hospital, Bremerhaven
MMW Fortschr Med 146:95-8. 2004A total of 487 patients with severe pain of varying pathogenesis received sustained-release hydromorphone (Palladon) in an observational study...
- Role of individual human cytochrome P450 enzymes in the in vitro metabolism of hydromorphoneS A Benetton
Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada
Xenobiotica 34:335-44. 2004..to identify the individual human cytochrome P450 (CYP) enzymes responsible for the in vitro N-demethylation of hydromorphone and to determine the potential effect of the inhibition of this metabolic pathway on the formation of other ..
- Equianalgesic dosing of opioidsHildegarde J Berdine
Department of Pharmacy Practice, Duquesne University Mylan School of Pharmacy, Pittsburgh, PA 15282, USA
J Pain Palliat Care Pharmacother 20:79-84. 2006The concept of opioid equianalgesia, limitations in current dose conversion systems, equianalgesic dose tables, and computer assisted dose conversions are discussed. Conversions for methadone, fentanyl and hydromorphone are described.
- Parent/nurse-controlled analgesia for children with developmental delayMichelle L Czarnecki
Jane B Pettit Pain and Palliative Care Center, Children s Hospital of Wisconsin, Milwaukee, WI 53201, USA
Clin J Pain 24:817-24. 2008..Parent/nurse-controlled analgesia (PNCA) may be an option for these children. However, the safety and efficacy of PNCA have not been thoroughly evaluated and many practitioners are reluctant to use it...
- Acetaminophen (paracetamol) improves pain and well-being in people with advanced cancer already receiving a strong opioid regimen: a randomized, double-blind, placebo-controlled cross-over trialMartin Stockler
Department of Medicine and School of Public Health, NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia
J Clin Oncol 22:3389-94. 2004..To determine whether adding regular acetaminophen (paracetamol) could improve pain and well-being in people with advanced cancer and pain despite strong opioids...
- Opioid self-administration in the nerve-injured rat: relevance of antiallodynic effects to drug consumption and effects of intrathecal analgesicsThomas J Martin
Department of Anesthesiology, Wake Forest University School of Medicine, NC 27157, USA
Anesthesiology 106:312-22. 2007..The authors examined the pharmacology of self-regulated intake of opioids in rats with or without nerve injury and compared the rate of drug intake to reversal of allodynia...
- The metamorphosis of hydromorphoneGary M Reisfield
Division of Palliative Medicine, Department of Community Health and Family Medicine, University of Florida Health Science Center Jacksonville, USA
J Opioid Manag 1:139-45. 2005b>Hydromorphone, one of the oldest and most potent of opioids, is an effective alternative to morphine. With a variety of routes of administration, it has an efficacy similar to that of morphine...
- Femoral nerve block for diaphyseal and distal femoral fractures in the emergency departmentBenedict A Rogers
J Bone Joint Surg Am 90:1787-8; author reply 1788-9. 2008
- Femoral nerve block for diaphyseal and distal femoral fractures in the emergency departmentChristopher E Mutty
Department of Orthopaedic Surgery, Wake Forest University Health Sciences, Medical Center Boulevard, Winston Salem, NC 27157, USA
J Bone Joint Surg Am 89:2599-603. 2007..The purpose of this study was to determine whether a femoral nerve block administered in the emergency department could provide better pain relief for patients with femoral fractures than currently used pain management practices...
- Equianalgesia: applying evidence-based practice guidelinesBruce S Bond
Our Lady of the Lake Regional Medical Center, Baton Rouge, LA, USA
Clin J Oncol Nurs 12:527-9. 2008
- Multiple opioids in pain managementRomayne Gallagher
Division of Palliative Care, University of British Columbia, Vancouver, Canada
Can Fam Physician 53:2119-20. 2007
- [Pharmacotherapy of chronic, non-tumour related pain. Efficacy, tolerability and patient benefit of an oral osmotic system with hydromorphone]Rainer Sabatowski
UniversitätsSchmerzCentrum, Klinik und Poliklinik für Anästhesiologie, Universitatsklinikum Carl Gustav Carus Dresden
MMW Fortschr Med 149:119-24. 2007An overview of the results of a clinical study is presented in which efficacy, tolerability and patient benefit of a therapy with OROS (ORal OSmotic) hydromorphone (Jurnista) in patients with chronic pain was investigated.
- The management of pain in children with life-limiting illnessesStefan J Friedrichsdorf
Pain and Palliative Care, Children s Hospitals and Clinics of Minnesota, 2525 Chicago Avenue South, Minneapolis, MN 55404, USA
Pediatr Clin North Am 54:645-72, x. 2007....
- Pain control via opioid analgesic-local anesthetic loaded IPNsDilek Sendil Keskin
Middle East Technical University, Department of Biological Sciences, Biotechnology Research Unit, Ankara 06531, Turkey
Curr Drug Deliv 1:57-64. 2004..study was designed for the construction of a controlled release system for local application of analgesics (hydromorphone (HM), morphine (M), and codeine (C)) and a local anesthetic, bupivacaine (BP)...
- Spontaneously breathing technique for opioid toleranceN Eipe
Acta Anaesthesiol Scand 52:575-6. 2008
- A randomized double-blind crossover comparison of continuous and intermittent subcutaneous administration of opioid for cancer painSharon Watanabe
Department of Symptom Control and Palliative Care, Cross Cancer Institute, Edmonton, Alberta, Canada
J Palliat Med 11:570-4. 2008..In all cases, patients and investigators expressed no preference for one modality over another. Further research is required to confirm that opioid administration by CSCI and ISCI provide similar analgesic and adverse effects...
- The detection of hydromorphone in urine specimens with high morphine concentrationsPamela C McDonough
Division of Forensic Toxicology, Office of the Armed Forces Medical Examiner, 1413 Research Blvd, Bldg 102, Rockville, MD 20850, USA
J Forensic Sci 53:752-4. 2008A previous study suggested that small amounts of morphine are metabolically converted to hydromorphone. In the present study, morphine positive urine specimens obtained from a postmortem laboratory and a random urinalysis program were ..
- Strategies to induce labor analgesia with epidural hydromorphoneJ M Mhyre
Int J Obstet Anesth 17:81-2. 2008
- Urine drug test interpretation: what do physicians know?Gary M Reisfield
Department of Community Health and Family Medicine, University of Florida College of Medicine Jacksonville, USA
J Opioid Manag 3:80-6. 2007..To determine the level of urine drug test (UDT) interpretive knowledge of physicians who use these instruments to monitor adherence in their patients on chronic opioid therapy...
- Stability and compatibility of drug mixtures in an implantable infusion systemF Bianchi
Codman Neuro Sciences SA RL, Le Locle, Switzerland
Anaesthesia 63:972-8. 2008..and the compatibility of mixtures of morphine sulphate, bupivacaine, and clonidine hydrochloride and of hydromorphone, bupivacaine, and clonidine hydrochloride, when used in constant flow implantable pumps under simulated ..
- Correlation between withdrawal symptoms and medication pump residual volume in patients with implantable SynchroMed pumpsJamal Taha
Division of Neurosurgery, Kettering Medical Center, Dayton, Ohio 45429, USA
Neurosurgery 55:390-3; discussion 393-4. 2004..Minneapolis, MN) develop symptoms of drug withdrawal at residual medication volumes that exceed 2 ml (the alarm residual volume recommended by the manufacturer)...
- The addition of hydromorphone to epidural fentanyl does not affect analgesia in early labourRobert K Parker
Department of Anesthesiology, Baystate Medical Center, Springfield, Massachusetts, USA
Can J Anaesth 49:600-4. 2002..The current study was designed to determine the influence of hydromorphone added to an epidural fentanyl bolus (e.g., whether there is an increase in duration of analgesia).
- Pain evaluation in patients receiving intravenous patient-controlled analgesia after surgeryGhassem E Larijani
Department of Anesthesiology, Cooper University Hospital, Camden, New Jersey, USA
Pharmacotherapy 25:1168-73. 2005..To evaluate the effectiveness of intravenous patient-controlled analgesia (PCA) in patients after surgery...
- Opioid rotation in the treatment of joint pain. A review of 67 casesR M Grilo
Rheumatology and Therapeutics Department, CHU Dupuytren, 2 Avenue Martin Luther King, 87042 Limoges, France
Joint Bone Spine 69:491-4. 2002..To determine that opioid rotation can be useful for establishing a more advantageous analgesia/toxicity relationship in rheumatologic pain...
- The effect of opioids on driving and psychomotor performance in patients with chronic painMichael G Byas-Smith
Department of Anesthesiology, Emory University School of Medicine, Atlanta, GA 30322, USA
Clin J Pain 21:345-52. 2005..The hypothesis was that patients with chronic pain on stable opioid analgesic regimens operate their automobiles safely with proficiency equal to normal volunteer controls...
- Use of the infusion pain pump following transverse rectus abdominis muscle flap breast reconstructionAlbert Losken
Emory Division of Plastic and Reconstructive Surgery, Paces Plastic Surgery, Atlanta, GA 30308, USA
Ann Plast Surg 54:479-82. 2005..received patient-controlled analgesia (PCA) (morphine, n = 34; meperidine (Demerol, Sanofi-Synthelabo), n = 1; hydromorphone hydrochloride (Dilaudid, Abbott Pharmaceutical) n = 1)...
- In vivo pain relief effectiveness of an analgesic-anesthetic carrying biodegradable controlled release rod systemsD Sendil-Keskin
Middle East Technical University, Department of Biological Sciences and Biotechnology, Biotechnology Research Unit, 06531 Ankara, Turkey
J Biomater Sci Polym Ed 14:497-514. 2003..We designed a controlled release system of pain relievers, mainly for opioids (morphine, M, codeine, C, and hydromorphone, HM), and a local anesthetic (bupivacaine, BP) in the form of poly(L-lactide-co-glycolide) (PLGA) rods...
- The use of opioids in the postoperative setting: focus on morphine, hydromorphone, and fentanylJulie Golembiewski
Departmetn of Pharmacy Practice, University of Illinois at Chicago, 60612 7230, USA
J Perianesth Nurs 20:141-3. 2005
- Antihyperalgesic effect of simultaneously released hydromorphone and bupivacaine from polymer fibers in the rat chronic constriction injury modelVasif Hasirci
Department of Biological Sciences, Biotechnology Research Unit, Middle East Technical University, Ankara, 06531, Turkey
Life Sci 73:3323-37. 2003We aimed to evaluate the antihyperalgesic efficacy of a combination of hydromorphone (HM) and bupivacaine (BP) delivered via controlled release from a biodegradable cylindrical rod...
- Contribution to variability in response to opioidsGeoffrey W Hanks
Department of Palliative Medicine, Bristol Haematology and Oncology Centre, University of Bristol, Horfield Road, Bristol, BS2 8ED, UK
Support Care Cancer 13:145-52. 2005..This article reviews factors that affect the efficacy and tolerability of opioid analgesics and clinical strategies for successful pain mangement...
- The risk of cesarean delivery with neuraxial analgesia given early versus late in laborCynthia A Wong
Department of Anesthesiology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
N Engl J Med 352:655-65. 2005..0 cm dilated) has been associated with an increased risk of cesarean delivery. It is unclear, however, whether this increase in risk is due to the analgesia or is attributable to other factors...
- Prospective audit of short-term concurrent ketamine, opioid and anti-inflammatory ('triple-agent') therapy for episodes of acute on chronic painP Good
Department of Medicine, Southern Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University and Medicine Program, Southern Health, McCulloch House, Monash Medical Centre, Melbourne, Victoria, Australia
Intern Med J 35:39-44. 2005..The clinical hypothesis in this study is that better pain control may be obtained by simultaneous multiple target receptor blockade...
- [Pain reduced and quality of life improved by sustained-release hydromorphone. Results of an observational study]H B Sittig
Schmerztherapie Zentrum, Unterweser, St Josef Hospital, Wienerstrasse 1, D 27568 Bremerhaven
MMW Fortschr Med 146:45. 2004
- Opioid Antagonist Discrimination: A Model of WithdrawalAlison Oliveto; Fiscal Year: 2011..Previously, we showed that the opioid agonist hydromorphone blocks the effects of NX while the partial opioid agonists nalbuphine and butorphanol, and the alpha2-..
- Characterization of Toxicity with Spinal OpiatesTony L Yaksh; Fiscal Year: 2010..Our studies show that granulomas are induced by morphine, hydromorphone, methadone and DAMGO, but not fentanyl...
- Opioid selection and the risk of serious infections in older adultsCarlos G Grijalva; Fiscal Year: 2013..g. codeine) reduces immunosuppression, and substitution of a carbonyl group at C6 (e.g. hydromorphone) eliminates the immunosuppressive effects...
- Optimizing Pain Treatment while Reducing Abuse Liability in Opioid DependenceDavid Andrew Tompkins; Fiscal Year: 2013..pain threshold and tolerance), subjective, and objective drug effects provided by intravenous doses of hydromorphone and buprenorphine in 3 groups: pain-free methadone maintained participants (N=30), pain-free buprenorphine ..
- A Delta/Kappa OR Ligand: Taking Advantage of Heteromers to Control PainBoris Tabakoff; Fiscal Year: 2013..These Phase I SBIR studies should set the stage for further development through the SBIR Phase II program and completion of pre-clinical work for a most promising pain medication. ..
- Abuse-deterrent sustained-release hydromorphoneMICHAEL ZAMLOOT; Fiscal Year: 2006..In 2005, Purdue Pharma plans to launch sustained-release hydromorphone, a more potent narcotic than oxycodone...
- Rapid Transdermal Delivery of Opioid Pain MedicationsAlan Smith; Fiscal Year: 2002..The opioid candidates to be tested in vitro with the thermal microporation method include morphine, hydromorphone, fentanyl, and alfentanil...
- HUMAN POLYDRUG USE: AND ECONOMIC ANALYSISRalph Spiga; Fiscal Year: 2001..STUDY 2 will examine methadone consumption when vehicle and hydromorphone are the concurrent drug alternatives...
- DYNORPHIN A OPIOID PEPTIDE--INTERACTIONS WITH MORPHINEBEHZAD KHOSROVI; Fiscal Year: 1993..a pilot study to evaluate the ability of dynorphin A (1- 13) to enhance the analgesic effect of morphine (or hydromorphone) in patients requiring relatively high doses of these opioids...
- NARCOTIC DRUG AND OPIOID PEPTIDE BASIC RESEARCH PROJECTJames Woods; Fiscal Year: 2002..PET imaging studies will compare buprenorphine's binding to central mu-opioid receptors with its antagonism of hydromorphone's pharmacological effects. Two of the areas of study are new...
- NARCOTIC DRUG AND OPIOID PEPTIDE BASIC RESEARCH PROJECTJames Woods; Fiscal Year: 2006..PET imaging studies will compare buprenorphine's binding to central mu-receptors with its antagonism of hydromorphone's pharmacological effects...
- Reducing Cocaine/Heroin Abuse with SR-Amphetamine and BuprenorphineMark Greenwald; Fiscal Year: 2009..in weeks 1-3) will: [1a] be safe and well tolerated;[1b] decrease choice of cocaine alone or combined with hydromorphone (HYD), relative to HYD alone and placebo on a choice progressive ratio schedule (4 conditions;randomized ..
- Human Laboratory Model of Cocaine Treatment: Behavioral Economic AnalysisMark K Greenwald; Fiscal Year: 2010....
- SEROTONIN Treatment of Cocaine DependenceERIC STRAIN; Fiscal Year: 2005....
- Liposomal Opioids Extend Analgesia in Laboratory AnimalsLisa Krugner Higby; Fiscal Year: 2008..Novel methods of time-release preparation for potent, pure agonist opioids such as oxymorphone and hydromorphone represent a significant refinement in the way in which these drugs are administered to both rodents and larger ..
- Molecular Genetics of Inattention in AustraliaTHEODORE CICERO; Fiscal Year: 2009..This will be at a marked cost savings due to the employment of existing well-characterized samples and the long history of collaborative studies between investigators from Australia and the United States. ..
- EVALUATION OF OPIOID ANTAGONIST ACTIVITY IN HUMANSEric C Strain; Fiscal Year: 2010....
- Hyperalgesia in Methadone Patients: Can it be Treated?Margaret Compton; Fiscal Year: 2007..abstract_text> ..
- OPIATE ENDOCRINE INTERACTIONS--DEVELOPMENTAL ASPECTSTHEODORE CICERO; Fiscal Year: 2003..The proposed animal studies could establish whether gender differences exist and if these differences are based on inherent, first-order biological differences between the sexes. ..
- Neuropharmacology of Tramadol: Clinical Efficacy and Abuse PotentialWILLIAM WALTON STOOPS; Fiscal Year: 2010..Developing analgesics with reduced abuse potential may reduce the prevalence of prescription opioid misuse and subsequent opioid use disorders. ..
- CLINICAL RESEARCH ON DRUG ABUSEERIC STRAIN; Fiscal Year: 2006..Thus, this ISA represents a good investment by NIDA. ..
- Evaluation of Atomoxetine for Cocaine Dependence: A Pilot TrialSharon Walsh; Fiscal Year: 2008..This study will provide preliminary safety and efficacy data on the potential utility of atomoxetine and determine whether a larger-scale evaluation is warranted. [unreadable] [unreadable] [unreadable]..
- GLUTAMATERGIC SYSTEMS IN PAIN AND OPIOID ACTIONCharles Inturrisi; Fiscal Year: 2008..unreadable] [unreadable] [unreadable]..
- Adulterants, drugs, coingestants and associated HIV riskEdward Boyer; Fiscal Year: 2008..Integrating analytical laboratory science into social science methods represents an innovative interdisciplinary approach to HIV research that will provide a basis for future research on these substances. ..
- Agonist Replacement Therapy for Cocaine Dependence: Identifying Novel MedicationsCRAIG RUSH; Fiscal Year: 2009..Identifying novel agonist replacement therapies is important because clinicians may be reluctant to use d-amphetamine because of its abuse potential. ..
- Role of the Amygdala in Opioid Self-administration in Rats with Chronic Pain.Thomas Martin; Fiscal Year: 2009....
- TMS in the Management of Postoperative PainJeffrey J Borckardt; Fiscal Year: 2010..Thus, new interventions that have the potential to reduce reliance on postoperative morphine in this patient population such as TMS need to be explored. ..
- New Neural Targets for Opioid Use Disorders: Human StudiesSharon L Walsh; Fiscal Year: 2010..Thus, these studies, conducted in healthy humans, will provide fundamental information regarding the potential for this system as a target for development of new treatment agents for opioid use disorders. ..
- AMINOBENZOMORPHAN: POTENTIAL COCAINE ABUSE MEDICATIONSMark Wentland; Fiscal Year: 2009..Radioligand binding, [35S]GTPvS, and mouse antinociceptive assays will be used to characterize new targets pharmacologically. ..
- PHARMACOLOGICAL MODULATION OF COCAINE EFFECTSGeorge Bigelow; Fiscal Year: 2002....
- Evaluation of Novel Treatments for Stimulant DependenceSharon Walsh; Fiscal Year: 2008..unreadable] [unreadable]..
- Factors in Drug DependenceSharon Walsh; Fiscal Year: 2005..abstract_text> ..
- AGING AND PERIOPERATIVE OUTCOMESJACQUELINE LEUNG; Fiscal Year: 2005..We believe that our studies will provide important results contributing ultimately to the improvement of perioperative outcomes in geriatric patients. ..
- PHARMACOLOGY OF COMBINED EPHEDRINE/CAFFEINE SUPPLEMENTSChristine Haller; Fiscal Year: 2004..The long-term objective for the proposed studies is to develop Dr. Haller into an independent career clinical researcher in this field of study. ..
- ASSESSING ABUSE POTENTIAL IN HUMAN--CNS STIMULANTSCRAIG RUSH; Fiscal Year: 2004..abstract_text> ..
- Relationship Between the Internet and Illicit Drug UseEdward Boyer; Fiscal Year: 2003..After addressing the study hypotheses, we will conduct exploratory analyses to compare respondents who do and do not use the Internet to obtain information on illicit drugs. ..
- GABA Agonists as Pharmacotherapies for Cocaine AbuseCRAIG RUSH; Fiscal Year: 2003..Finally, the proposed research will allow us to conduct retrospective analyses to determine the influence of individual differences (e.g., gender, other drug use) on the reinforcing and subjective effects of cocaine. ..
- THERAPEUTIC POTENTIAL OF KAPPA-OPIOIDS AGAINST COCAINESharon Walsh; Fiscal Year: 2002..These studies are relevant to the treatment of cocaine abuse and may lead to the development of an effective pharmacotherapy, thereby, reducing the HIV and other health risks associated with cocaine abuse and intravenous drug abuse. ..
- HUMAN BEHAVIORAL PHARMACOLOGY OF DRUG ABUSEGeorge Bigelow; Fiscal Year: 2002..The cocaine dependence clinical trials will evaluate the efficacy of the serotonergic agents tryptophan and fluoxetine in the context of an incentive-based behavior therapy program. ..
- Human Cocaine DiscriminationCRAIG RUSH; Fiscal Year: 2006..Elucidating the role of dopamine in mediating the effects of cocaine may guide the development of pharmacological interventions for cocaine. ..
- Nasal Delivery of Naltrexone for Treatment of AlcoholismDaniel Wermeling; Fiscal Year: 2006..The long-term goal of this work is to develop and commercialize nasal delivered NTX for the treatment of alcoholism. [unreadable] [unreadable] [unreadable]..
- Sublingual Buprenorphine for Chronic Pain in Patients at Risk for Drug AbuseAndrew Rosenblum; Fiscal Year: 2007..unreadable] [unreadable] [unreadable]..
- Opioids, internet pharmacies, self-treated chronic pain, and HIV/AIDSEdward Boyer; Fiscal Year: 2007..abstract_text> ..
- Cost and Adherence in Drug Abuse TreatmentKENNETH STOLLER; Fiscal Year: 2007..This accomplishment will document my transition to the status of an independent patient-oriented researcher and recognized expert in the field of drug abuse treatment. [unreadable] [unreadable] [unreadable] [unreadable]..
- RVM CCK, Pain, and Opioid ToleranceTodd Vanderah; Fiscal Year: 2006..These approaches may allow for sustained efficacy of morphine or opioids and their use in the treatment of chronic or prolonged pain states. ..
- Glutamate receptors in pain and addictive behaviorsCharles Inturrisi; Fiscal Year: 2007..This SSA award will also allow me to continue the reduction in teaching and administrative responsibilities that has significantly increased the time I was able to devote to enhancing my scientific skills. ..
- Stimulant Abuse Pharmacotherapy: Novel AntipsychoticsCRAIG RUSH; Fiscal Year: 2009..The proposed research will provide initial scientific and clinical information regarding the use of aripiprazole as a pharmacotherapy for the treatment of methamphetamine dependence, and guide the design of future clinical trials. ..
- NOVEL NONPEPTIDE LIGANDS FOR THE OPIOID RECEPTORSSubramaniam Ananthan; Fiscal Year: 2007..unreadable] [unreadable] [unreadable]..
- Preventing Cocaine Relapse: Developing PharmacotherapiesCRAIG RUSH; Fiscal Year: 2008..Reducing relapse to drug use is important because intravenous abuse of cocaine may be associated with increased risk of acquired immunodeficiency syndrome (A.I.D.S.). ..
- 2,5 CYCLOHEXADIENONES IN NATURAL PRODUCTS SYNTHESISMark Wentland; Fiscal Year: 2001....